← Back
Data updated: Mar 10, 2026
TAGI
Ophthalmology
TAGI is a generic drug manufacturer focused on Ophthalmology. Key products include DEXMEDETOMIDINE HYDROCHLORIDE.
2020
Since
2
Drugs
-
Trials
16
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
DEXMEDETOMIDINE HYDROCHLORIDE 2026-02-17
Labeling
METHAZOLAMIDE 2026-02-09
DEXMEDETOMIDINE HYDROCHLORIDE 2025-04-16
Labeling
DEXMEDETOMIDINE HYDROCHLORIDE 2025-04-16
Labeling
DEXMEDETOMIDINE HYDROCHLORIDE 2025-03-28
Labeling
DEXMEDETOMIDINE HYDROCHLORIDE 2025-03-28
Labeling
DEXMEDETOMIDINE HYDROCHLORIDE 2025-03-28
Labeling
DEXMEDETOMIDINE HYDROCHLORIDE 2024-12-19
Manufacturing (CMC)
DEXMEDETOMIDINE HYDROCHLORIDE 2024-11-06
Labeling
DEXMEDETOMIDINE HYDROCHLORIDE 2024-11-06
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Ophthalmology 100%
1 drugs
Pipeline Strength Pro
Loading...
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2020-11-23
- Latest
- 2026-02-17
- Applications
- 2